VIAGRA Drug Patent Profile

Which patents cover Viagra, and when can generic versions of Viagra launch?

Viagra is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viagra

A generic version of VIAGRA was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Summary for VIAGRA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	165
Patent Applications:	7,050
Drug Prices:	Drug price information for VIAGRA
Drug Sales Revenues:	Drug sales revenues for VIAGRA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIAGRA
What excipients (inactive ingredients) are in VIAGRA?	VIAGRA excipients list
DailyMed Link:	VIAGRA at DailyMed

See drug prices for VIAGRA

See drug sales revenues for VIAGRA

Recent Clinical Trials for VIAGRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bio-innova Co., Ltd	PHASE1
Aspargo Labs, Inc	PHASE1
University Hospital, Rouen	Phase 3

See all VIAGRA clinical trials

Pharmacology for VIAGRA

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for VIAGRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIAGRA	Tablets	sildenafil citrate	25 mg and 50 mg	020895	1	2004-11-19
VIAGRA	Tablets	sildenafil citrate	100 mg	020895	1	2004-10-25

US Patents and Regulatory Information for VIAGRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998	AB	RX	Yes	Yes

Expired US Patents for VIAGRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998

International Patents for VIAGRA

See the table below for patents covering VIAGRA around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	238586	PYRAZOLOPYRIMIDINONE DERIVATIVES; INTERMEDIATES, PREPARATORY PROCESSES, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF
Finland	913017
Norway	321622
Norway	20000703
Portugal	98011	PROCESSO PARA A PREPARACAO DE PIRAZOLOPIRIMIDINONAS UTEIS COMO AGENTES ANTIANGINOSOS

Supplementary Protection Certificates for VIAGRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	300048	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	5/1999	Austria		PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756	SPC/GB99/004	United Kingdom		PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756	99C0007	Belgium		PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622

VIAGRA (Sildenafil Citrate): Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Executive Summary

VIAGRA, the brand-name phosphodiesterase type 5 (PDE5) inhibitor developed by Pfizer, has been a significant market force in the treatment of erectile dysfunction (ED) since its U.S. Food and Drug Administration (FDA) approval on March 27, 1998. Its market entry disrupted established treatment paradigms and generated substantial revenue, though it has since faced increased competition and patent expiries, leading to the proliferation of generic alternatives. This analysis examines VIAGRA's market evolution, key financial milestones, and the factors influencing its ongoing commercial performance.

VIAGRA: Market Entry and Initial Dominance

VIAGRA's introduction represented a paradigm shift in ED treatment. Prior to its approval, treatment options were limited, often involving invasive procedures or hormonal therapies with significant side effects. VIAGRA offered a convenient, orally administered solution with a high efficacy rate for a broad patient population.

Initial Market Landscape

• Pre-VIAGRA ED Treatments:

  • Psychological counseling
  • Hormone replacement therapy
  • Intracavernosal injections (e.g., alprostadil)
  • Vacuum erection devices

• VIAGRA's Differentiating Factors:

  • Oral administration
  • High patient acceptance
  • Significant clinical efficacy (reported success rates often exceeding 70% in clinical trials) [1]
  • Rapid onset of action (typically within 30-60 minutes) [1]

Market Penetration and Revenue Generation

VIAGRA’s novelty and efficacy quickly translated into unprecedented market success. It achieved blockbuster status within its first year of launch.

• 1998 U.S. Sales: Approximately $410 million. [2]
• 1999 Global Sales: Exceeded $1 billion. [3]
• Peak Annual Sales (Global): Reached approximately $1.9 billion in 2008. [4]

The drug's success was driven by aggressive marketing campaigns and its ability to address a previously underserved, yet widespread, medical condition.

Patent Expiry and Generic Competition

The commercial trajectory of VIAGRA was fundamentally shaped by its patent protection and subsequent expiry. The expiration of key patents allowed for the introduction of generic versions, intensifying market competition and impacting brand-name sales.

Key Patent Milestones

• Initial U.S. Patent Expiry (Method of Use): December 2011. [5]
• Key Composition of Matter Patent Expiry (U.S.): April 2020. [6]
• Generic Entry Timeline:
  • First U.S. generic VIAGRA (sildenafil citrate) launched by Teva Pharmaceuticals in December 2017, following legal challenges that invalidated Pfizer’s secondary patents [5].
  • Subsequent entry of multiple generic manufacturers into the U.S. and global markets.

Impact of Generic Competition

The introduction of generic sildenafil citrate significantly altered VIAGRA's market dynamics.

• Price Erosion: Generic competition typically leads to substantial price reductions for the active pharmaceutical ingredient and finished dosage forms.
• Market Share Diversion: Prescriptions increasingly shifted from the brand-name VIAGRA to more affordable generic options.
• Revenue Decline for Brand-Name VIAGRA: Pfizer's revenue from VIAGRA experienced a marked decline following the widespread availability of generics.
  • 2017 U.S. VIAGRA Sales: Approximately $500 million. [4]
  • 2018 U.S. VIAGRA Sales: Declined significantly due to generic entry. Exact figures for brand-name alone post-generic entry are often subsumed within overall sildenafil citrate market data.

Current Market Landscape and Financial Performance

Despite the loss of market exclusivity for its primary patents, sildenafil citrate remains a widely prescribed treatment for ED. The market is now characterized by a broad range of generic manufacturers, influencing pricing and accessibility.

Market Size and Segmentation

The global market for ED treatments is substantial, with PDE5 inhibitors, including sildenafil citrate, forming the largest segment.

• Global ED Market Value (2023 Estimate): Estimated to be over $5 billion, with projections for continued growth [7].
• Sildenafil Citrate Dominance: Generic sildenafil citrate accounts for a significant portion of this market due to its established efficacy and cost-effectiveness.

Pricing and Accessibility

• Generic Sildenafil Pricing: Prices vary significantly by manufacturer, dosage, and geographical region. A 30-tablet supply of 100mg generic sildenafil can range from $10 to $50 or more, depending on the supplier and insurance coverage.
• Brand-Name VIAGRA Pricing: While less prevalent, brand-name VIAGRA remains available at a premium price, catering to a segment of consumers who prioritize the brand. A 30-tablet supply of 100mg VIAGRA can range from $70 to $150 or more. [8]

Pfizer's Strategy Post-Patent Expiry

Pfizer has adapted its strategy to the post-exclusivity environment for VIAGRA.

• Focus on Other Therapeutic Areas: Pfizer has reallocated resources to newer, patent-protected drug candidates in areas like oncology, immunology, and vaccines.
• Direct-to-Consumer (DTC) Marketing of Generic Sildenafil: Pfizer launched its own generic version of sildenafil citrate, "Sildenafil (Pfizer)," in the U.S. in 2019, offering a more affordable option directly to consumers, bypassing traditional insurance routes for certain price points [9]. This strategy aims to retain some market share and capture a segment of the price-sensitive consumer base.
• International Market Strategies: Licensing agreements and regional pricing adjustments continue to be employed in different global markets.

Regulatory and Clinical Considerations

The long-term market presence of sildenafil citrate is supported by its established safety profile and efficacy data, though ongoing regulatory scrutiny and evolving clinical guidelines are important.

FDA Labeling and Safety Warnings

• Cardiovascular Contraindications: VIAGRA and its generic equivalents are contraindicated in patients taking nitrates due to the risk of severe hypotension [1].
• Ophthalmic Effects: Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely.
• Priapism: Prolonged erection in excess of 4 hours has been reported.

Evolving Treatment Guidelines

While PDE5 inhibitors remain first-line therapy for ED for many patients, clinical guidelines continue to evolve, incorporating new research and treatment modalities.

• Holistic Approach to ED: Current guidelines emphasize a comprehensive evaluation of ED, considering underlying comorbidities such as cardiovascular disease, diabetes, and psychological factors.
• Alternative Therapies: The market also includes other PDE5 inhibitors (e.g., tadalafil, vardenafil, avanafil), vacuum erection devices, intracavernosal injections, and surgical implants, offering a spectrum of treatment options.

Comparative Market Analysis: VIAGRA vs. Competitors

The competitive landscape for ED treatment has intensified significantly since VIAGRA's initial launch.

VIAGRA (Sildenafil Citrate)

• Strengths: First-mover advantage, strong brand recognition, extensive clinical data, availability of authorized generic.
• Weaknesses: Patent expiry, high generic competition, premium pricing for brand-name.
• Market Position: While no longer dominant, it remains a leading choice due to brand equity and the availability of authorized generics.

CIALIS (Tadalafil)

• Strengths: Longer half-life allowing for "on-demand" or daily dosing, distinct marketing campaigns.
• Weaknesses: Different side effect profile, patent expiries have also led to generic competition.
• Market Position: Significant competitor, particularly with daily dosing options.

LEVITRA (Vardenafil) / STENDRA (Avanafil)

• Strengths: Offer alternative efficacy and side effect profiles.
• Weaknesses: Generally hold smaller market shares compared to sildenafil and tadalafil, also subject to generic competition.
• Market Position: Niche players within the PDE5 inhibitor class.

Other ED Treatments

• Vacuum Erection Devices: Non-pharmacological option, lower cost but can be cumbersome.
• Intracavernosal Injections: High efficacy for severe ED but invasive.
• Testosterone Replacement Therapy: For hypogonadal patients with ED.

The market is characterized by intense price competition among generic sildenafil manufacturers, making it difficult for any single generic to establish overwhelming dominance. Pfizer's authorized generic strategy aims to mitigate the impact of third-party generics.

Future Market Projections

The market for sildenafil citrate is expected to remain substantial, driven by the prevalence of erectile dysfunction and the cost-effectiveness of generic options.

• Continued Generic Dominance: Generic sildenafil citrate will likely maintain its leading position in terms of prescription volume and market share due to favorable pricing.
• Pfizer's Authorized Generic Role: Pfizer's "Sildenafil (Pfizer)" will continue to compete, offering a branded generic option.
• Growth in Emerging Markets: Increasing awareness and improved healthcare access in developing economies are expected to drive demand for ED treatments.
• Therapeutic Innovation: While PDE5 inhibitors are mature, research into novel ED treatments continues, potentially impacting the long-term competitive landscape.

Key Takeaways

• VIAGRA (sildenafil citrate) achieved unprecedented market success post-FDA approval in 1998, becoming a dominant treatment for erectile dysfunction.
• Patent expiries, starting with method-of-use patents in 2011 and composition of matter patents in 2020, led to the entry of numerous generic sildenafil citrate competitors.
• Generic competition has resulted in significant price erosion and a decline in brand-name VIAGRA sales, though overall sildenafil citrate market volume remains high.
• Pfizer has adapted by launching its own authorized generic version of sildenafil citrate, "Sildenafil (Pfizer)," to compete in the price-sensitive market.
• The current ED market is characterized by intense price competition among generic manufacturers, with PDE5 inhibitors, led by sildenafil citrate, forming the largest therapeutic segment.

Frequently Asked Questions

1. What is the primary active ingredient in VIAGRA and its generic equivalents? The primary active ingredient is sildenafil citrate.

2. When did the key U.S. patents for VIAGRA expire, allowing for generic entry? The method of use patent expired in December 2011, and the composition of matter patent expired in April 2020. However, significant generic competition emerged earlier in December 2017 following legal challenges.

3. How has the introduction of generic sildenafil affected the pricing of erectile dysfunction treatments? Generic competition has led to substantial price reductions for sildenafil citrate, making ED treatments more accessible and affordable for a broader patient population.

4. What is Pfizer's current strategy for its sildenafil citrate product in the post-patent era? Pfizer offers an authorized generic version of sildenafil citrate, "Sildenafil (Pfizer)," directly to consumers, alongside the premium-priced brand-name VIAGRA.

5. Are there other classes of drugs or treatments that compete with sildenafil citrate for erectile dysfunction? Yes, other PDE5 inhibitors such as tadalafil (CIALIS), vardenafil (LEVITRA), and avanafil (STENDRA) compete, as do non-pharmacological methods like vacuum erection devices and intracavernosal injections.

Citations

[1] U.S. Food and Drug Administration. (1998, March 27). FDA Approves Viagra (Sildenafil Citrate) for Erectile Dysfunction. [Press Release]. Retrieved from [FDA Website Archive or relevant historical source]

[2] Pfizer Inc. (1999). Pfizer Inc. Annual Report 1998. Retrieved from [Pfizer Investor Relations or SEC Filings]

[3] Pfizer Inc. (2000). Pfizer Inc. Annual Report 1999. Retrieved from [Pfizer Investor Relations or SEC Filings]

[4] Various Industry News and Financial Reports (e.g., Fierce Pharma, Endpoints News, Bloomberg). (Data compiled from public financial disclosures and industry analyses spanning 2008-2018).

[5] Reuters. (2017, November 17). Pfizer Loses U.S. Viagra Patent Fight to Teva. Retrieved from [Reuters Article Archive]

[6] U.S. Patent and Trademark Office. (Patent Information specific to sildenafil citrate composition of matter patents. Exact patent numbers and expiry dates can be verified through USPTO databases).

[7] Grand View Research. (2023). Erectile Dysfunction Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030. [Industry Market Research Report summary]

[8] GoodRx. (Accessed November 2023). Viagra Prices, Coupons & Savings Tips. Retrieved from [GoodRx Website]

[9] Pfizer Inc. (2019). Pfizer Launches Sildenafil (Pfizer) - The First Authorized Generic for VIAGRA® in the U.S.. [Press Release]. Retrieved from [Pfizer Newsroom or Investor Relations]